V Tozzi

Summary

Affiliation: National Institute for Infectious Diseases
Country: Italy

Publications

  1. ncbi Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy
    Maria Letizia Giancola
    Clinical Department, Lazzaro Spallanzani National Institute for Infectious Diseases, Instituto di Ricovero e Cura a Carattere Scientifico IRCCS, Via Portuense 292, 00149 Rome, Italy
    J Acquir Immune Defic Syndr 41:332-7. 2006
  2. ncbi Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART
    V Tozzi
    Fourth Division of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Int J STD AIDS 15:254-9. 2004
  3. ncbi Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, 00149 Rome, Italy
    AIDS Res Hum Retroviruses 21:706-13. 2005
  4. ncbi Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    J Neurovirol 11:265-73. 2005
  5. ncbi Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Antivir Ther 11:553-60. 2006
  6. ncbi Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors
    Valerio Tozzi
    National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, Rome, Italy
    J Acquir Immune Defic Syndr 45:174-82. 2007
  7. ncbi Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    J Infect Dis 189:1688-95. 2004
  8. ncbi HIV pharmacogenetics in clinical practice: recent achievements and future challenges
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Curr HIV Res 6:544-54. 2008
  9. ncbi Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    J Acquir Immune Defic Syndr 52:56-63. 2009
  10. ncbi Neurocognitive performance and quality of life in patients with HIV infection
    Valerio Tozzi
    4th Division of Infectious Diseases, I N M I Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy
    AIDS Res Hum Retroviruses 19:643-52. 2003

Detail Information

Publications53

  1. ncbi Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy
    Maria Letizia Giancola
    Clinical Department, Lazzaro Spallanzani National Institute for Infectious Diseases, Instituto di Ricovero e Cura a Carattere Scientifico IRCCS, Via Portuense 292, 00149 Rome, Italy
    J Acquir Immune Defic Syndr 41:332-7. 2006
    ..To analyze the effect of antiretroviral therapy, including drugs that have good penetration in cerebrospinal fluid (CSF), on neuropsychologic performance...
  2. ncbi Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART
    V Tozzi
    Fourth Division of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Int J STD AIDS 15:254-9. 2004
    ..Neurocognitive impairment in patients receiving HAART was associated with reduced HRQoL. Identifying cognitive impairment may provide motivation for additional treatment to help patients to compensate for deficits in functioning...
  3. ncbi Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, 00149 Rome, Italy
    AIDS Res Hum Retroviruses 21:706-13. 2005
    ....
  4. ncbi Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    J Neurovirol 11:265-73. 2005
    ....
  5. ncbi Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Antivir Ther 11:553-60. 2006
    ..Drug-class-wide resistance (DCWR) to antiretrovirals substantially reduces treatment options...
  6. ncbi Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors
    Valerio Tozzi
    National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, Rome, Italy
    J Acquir Immune Defic Syndr 45:174-82. 2007
    ..We assessed the prevalence and predictors of persistent NP deficits despite long-term HAART in patients with HIV-related NCI...
  7. ncbi Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    J Infect Dis 189:1688-95. 2004
    ..We evaluated the effect of RT mutations associated with hypersusceptibility to NNRTIs on the response to efavirenz-based therapy...
  8. ncbi HIV pharmacogenetics in clinical practice: recent achievements and future challenges
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Curr HIV Res 6:544-54. 2008
    ..The aim of the present paper is to provide HIV clinicians with a comprehensive review of recent achievements and future prospects for HIV pharmacogenetics...
  9. ncbi Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    J Acquir Immune Defic Syndr 52:56-63. 2009
    ..We compared 2 ranking systems to measure HAART neuroeffectiveness...
  10. ncbi Neurocognitive performance and quality of life in patients with HIV infection
    Valerio Tozzi
    4th Division of Infectious Diseases, I N M I Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy
    AIDS Res Hum Retroviruses 19:643-52. 2003
    ..Cognitive impairment in any cognitive domain explored in our battery is also associated with poor QoL. Poor performance on the Digit Symbol Test is the strongest predictor of poor QoL...
  11. ncbi Managing patients with sexual transmission of drug-resistant HIV
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Sex Health 2:135-42. 2005
    ..The aim of the paper is to help clinicians to deal with patients presenting a PHI due to drug-resistant variants...
  12. ncbi Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, 00149 Rome, Italy
    AIDS Res Hum Retroviruses 24:787-96. 2008
    ..In contrast, early changes in PVL levels were not. Virologic failure was associated with detection of emergent DRMs. Virologic rebound in patients on salvage-HAART should be addressed aggressively...
  13. ncbi Pharmacogenetics of antiretrovirals
    Valerio Tozzi
    National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Antiviral Res 85:190-200. 2010
    ..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010...
  14. ncbi Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy
    Marco Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    HIV Clin Trials 11:303-11. 2010
    ..To investigate the risk factors for an HIV-1 RNA plasma viral load above 400 copies/mL in the third trimester of pregnancy...
  15. ncbi Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure
    M Zaccarelli
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149, Rome, Italy
    Infection 37:203-9. 2009
    ..To assess the role of viral suppression on clinical progression following a genotypic resistance test (GRT), we have examined a database on patients failing to respond to combined antiretroviral therapy (cART)...
  16. ncbi Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years
    V Tozzi
    Fourth Division of Infectious Diseases, I.R.C.C.S. Lazzaro Spallanzani, Rome, Italy
    J Acquir Immune Defic Syndr 28:19-27. 2001
    ....
  17. ncbi Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation
    Mauro Zaccarelli
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Antivir Ther 8:51-6. 2003
    ..M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment...
  18. ncbi Voluntary pregnancy termination among women with HIV in the HAART era (2002-2008): a case series from a national study
    Marco Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    AIDS Care 22:50-3. 2010
    ..Women with low CD4 counts and those with an HIV-infected partner represent two groups that should receive particular attention in preventive strategies...
  19. ncbi Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008
    M C F Prosperi
    Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    HIV Med 12:174-82. 2011
    ....
  20. ncbi Determinants of health-related quality of life in HIV-infected patients
    R Murri
    Department of Infectious Diseases, Catholic University, Rome, Italy
    AIDS Care 15:581-90. 2003
    ..Among these factors, symptoms, recent hospitalization and satisfaction with information are most amenable to clinical intervention...
  21. ncbi Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy
    A Antinori
    National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
    AIDS 15:1579-81. 2001
    ..Women receiving glucocorticoids had a 3 month cumulative probability of rash of 0.41...
  22. ncbi Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals
    Maria Paola Trotta
    Istituto Nazionale per le Malattie Infettive, L Spallanzani IRCCS, Rome, Italy
    AIDS Patient Care STDS 22:291-9. 2008
    ..44; 95% CI 1.30-9.08). In conclusion, patients' perceived SD represents a relevant problem for HIV-infected persons treated with antiretrovirals and is strongly associated with suboptimal HAART adherence...
  23. ncbi Metabolic and morphologic disorders in patients treated with highly active antiretroviral therapy since primary HIV infection
    P Narciso
    Clinical Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy
    Ann N Y Acad Sci 946:214-22. 2001
    ..3 per 100 patient-years. CONCLUSIONS: Dyslipidemia and lipodystrophy can occur in patients treated with HAART since PHI. This risk of should be taken into account when considering this early antiretroviral treatment of HIV infection...
  24. ncbi Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration
    Silvia Baroncelli
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    Ann Pharmacother 44:838-43. 2010
    ..The safety and efficacy of both drugs have been investigated, but there is no information on possible pharmacokinetic interactions between these 2 drugs in clinical practice...
  25. ncbi Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study
    M C F Prosperi
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Clin Infect Dis 50:1316-21. 2010
    ..9-3.1 cases per 1000 person-years of follow-up), respectively. Lower current CD4 cell count was an independent predictor of developing malignancies, with the association being stronger for ADM than for NADM...
  26. ncbi Acute disseminated encephalomyelitis as manifestation of primary HIV infection
    P Narciso
    Fourth Clinical Division, National Institute for Infectious Diseases I R C C S Lazzaro Spallanzani, Rome, Italy
    Neurology 57:1493-6. 2001
    ..Improvements in the clinical and MRI findings and a reduction in HIV RNA levels, both in plasma and in the CSF, were observed during highly active antiretroviral therapy...
  27. ncbi An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects
    G D'Offizi
    National Institute for Infectious Diseases, Lazzaro Spallanzani I R C C S, Rome, Italy
    Int J Immunopathol Pharmacol 20:473-85. 2007
    ..In early-treated HIV+ patients undergoing STI, HIV replication control was associated to CD8 T cell maturation and sustained IL-15 levels, leading to HIV-specific CD8 T cell responses against selected Gag and Nef epitopes...
  28. ncbi Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome, Tor Vergata, Rome, Italy
    J Antimicrob Chemother 58:714-22. 2006
    ..To investigate gp41 variability and correlation with viro-immunological parameters in 54 HIV-1-infected patients receiving enfuvirtide added as single active drug to a failing regimen...
  29. ncbi Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes
    Silvia Baroncelli
    Department of Drug Research and Evaluation, Istituto Superiore di Sanità ISS, Rome, Italy
    AIDS Patient Care STDS 23:513-20. 2009
    ..Constant improvements in the rates of HIV suppression were observed, probably driven by the adoption of stronger and more effective regimens and by the increasing options available for combination treatment...
  30. ncbi Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy
    M Massella
    Istituto Superiore Sanita, Rome, Italy
    Patient Prefer Adherence 5:223-8. 2011
    ..Although these results cannot be considered representative because of important limitations, the present study suggests the severity of disease as an important determinant of costs...
  31. ncbi Historical resistance profile helps to predict salvage failure
    Mauro Zaccarelli
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Antivir Ther 14:285-91. 2009
    ....
  32. ncbi Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women
    Jelena Ivanovic
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Curr HIV Res 7:620-5. 2009
    ....
  33. ncbi Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy
    Mauro Zaccarelli
    Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Rome, Italy
    Clin Infect Dis 38:433-7. 2004
    ..A full reversion of the Q151M mutation was observed in 5 of 5 patients who underwent treatment interruption after GRT. The reversion was followed by a response to salvage therapy in 4 (80%) of 5 patients...
  34. ncbi The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy
    Bruno Christian Ciancio
    Clinical Department and Laboratory of Antiviral and Antineoplastic Drug Monitoring, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Roma, Italy
    Antivir Ther 8:611-6. 2003
    ..GRT and as-long-as-possible sparing of a drug class could be a convenient strategy for long-term management of drug-failing patients...
  35. ncbi Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir
    Maria Paola Trotta
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
    J Med Virol 78:535-41. 2006
    ..However, exposure to abacavir and/or efavirenz, presence of Q151M and/or L100I, and prior AIDS may favor the selection of this mutation. Conversely, long 3TC exposure, and the presence of M184V or NAMs seem to be protective...
  36. ncbi Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients
    Andrea Antinori
    National Institute for Infectious Diseases L Spallanzani IRCCS, Roma
    Antivir Ther 11:233-43. 2006
    ..To evaluate antiviral efficacy of stavudine/tenofovir (d4T/TDF) backbone combination in late-line antiretroviral therapy, and to assess clinical and virological determinants of treatment success...
  37. ncbi Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients
    Dora Larussa
    Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS, Rome, Italy
    AIDS Res Hum Retroviruses 22:386-92. 2006
    ..These results may have significant implications for the clinical management of the older HIV population...
  38. ncbi Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients
    Mauro Zaccarelli
    Clinical Department bLaboratory of Antiviral Drug Monitoring, National Institute of Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
    AIDS 19:1081-9. 2005
    ..To evaluate the effect of drug class-wide resistance (CWR) on survival in HIV-infected individuals who underwent genotypic resistance test after antiretroviral failure...
  39. ncbi The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage?
    Mauro Zaccarelli
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Curr HIV Res 2:283-92. 2004
    ..Phenotypic hypersusceptibility has been demonstrated for all three drug classes. Particularly, NNRTI hypersusceptibility, associated with NRTI mutations, is analyzed and discussed...
  40. ncbi The V118I mutation as a marker of advanced HIV infection and disease progression
    Mauro Zaccarelli
    Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    Antivir Ther 12:163-8. 2007
    ..We focused on the V1181 mutation in order to evaluate factors associated with its detection and its relationship with HIV progression...
  41. ncbi Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients
    Andrea Antinori
    National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
    AIDS 16:1867-76. 2002
    ..To determine the effectiveness of antiretroviral therapy in controlling cerebrospinal fluid (CSF) HIV-1 replication and to assess factors related to virological response in advanced patients...
  42. ncbi Impact of antiretroviral dosing frequency and daily pill burden on virological success rates in patients of the ICoNA cohort starting their first ART
    A Ammassari
    National Institute for Infectious Diseases, Rome, Italy
    J Int AIDS Soc 15:18233. 2012
    ..85 [0.73-0.98]). Once-a-day dosing of ART, especially when combined with low daily pill burden, seems to be one of main factors contributing to the higher rate of success of ART in recent years...
  43. ncbi Comparison of screening tools for the detection of neurocognitive impairment in HAART-treated patients
    A Antinori
    INMI L Spallanzani, Rome, Italy
    J Int AIDS Soc 15:18286. 2012
    ..Combining IHDS with one or two simple NP test may represent an improvement in the screening approach to the detection of both NCI and HAND...
  44. ncbi Factors influencing gestational age-adjusted birthweight in a national series of 600 newborns from mothers with HIV
    Marco Floridia
    Department of Drug Research and Evaluation, Istituto Superiore di Sanità ISS, Rome, Italy
    HIV Clin Trials 9:287-97. 2008
    ..Few studies have assessed the determinants of birthweight in newborns from HIV-positive mothers in analyses that adjusted for different gestational age at delivery...
  45. ncbi T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy
    R Bucciardini
    Istituto Superiore di Sanita, Rome, Italy
    Biologics 2:577-81. 2008
    ..To evaluate the impact of health-related quality of life (HRQoL) enfuvirtide-based (ENF-based) salvage regimens of treatment-experienced HIV patients, in an observational multicenter cohort study...
  46. ncbi Declining HCV seroprevalence in pregnant women with HIV
    M Floridia
    Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
    Epidemiol Infect 138:1317-21. 2010
    ..03-0.29]. Previous IDU was the stronger determinant of HCV co-infection in pregnant women with HIV (aOR 30.9, 95% CI 18.8-51.1). The observed trend is expected to translate into a reduced number of cases of vertical HCV transmission...
  47. ncbi High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy
    Enrico Girardi
    Dipartimento di Epidemiologia and Dipartimento Clinico, Istituto Nazionale per le Malattie Infettive L. Spallanzani, IRCCS, Rome, Italy
    AIDS 16:1976-9. 2002
  48. ncbi Therapeutic drug monitoring in the management of HIV-infected patients
    Jelena Ivanovic
    Istituto Nazionale per le Malattie Infettive IRCCS Lazzaro Spallanzani, Via Portuense 292, I 00149 Roma, Italy
    Curr Med Chem 15:1925-39. 2008
    ..Here, the basic principles and the available methods for TDM in the management of HIV-infected patients are reviewed...
  49. ncbi Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study
    Pasquale Narciso
    National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    AIDS Res Hum Retroviruses 25:979-87. 2009
    ..Studies should be performed to identify patients who could maximally benefit from filling interventions for FLA...
  50. ncbi Monophyletic HIV type 1 CRF02-AG in a nosocomial outbreak in Benghazi, Libya
    Ubaldo Visco-Comandini
    National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
    AIDS Res Hum Retroviruses 18:727-32. 2002
    ..The data thus suggest a highly contagious nosocomial spread of HIV-1 infection and possibly transmission of the virus from child to mother during breastfeeding in connection with primary HIV-1 infection...
  51. ncbi Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance
    Rita Murri
    Clinica delle Malattie Infettive, Universita Cattolica del S Cuore, 00168 Rome, Italy
    J Gen Intern Med 19:1104-10. 2004
    ..To evaluate the rate of discordance between patients and physicians on adherence to highly active antiretroviral therapy (HAART) and identify factors related to discordance in these two assessments...
  52. ncbi Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy
    Maria Mercedes Santoro
    Department of Experimental Medicine, Tor Vergata University of Rome, Italy
    New Microbiol 29:89-100. 2006
    ....
  53. ncbi Possible child-to-mother transmission of HIV by breastfeeding
    Ubaldo Visco-Comandini
    JAMA 294:2301-2. 2005